Willis Towers Watson enjoys organic growth but withdraws 2020 guidance over COVID-19
Broker Willis Towers Watson has withdrawn its full-year 2020 guidance due to "uncertainties" caused by the pandemic. Although it enjoyed a 4 percent organic revenue growth in the first quarter, supported by no material adverse impact from COVID-19.
WTW, however, expects COVID-19-related economic impact to negatively affect its revenues and operating results for the remainder of 2020. Hence, the broker has reinforced its focus on "maintaining a strong balance sheet, liquidity, and financial flexibility".
The company grew its revenue 7 percent to $2.5 billion, with constant currency growth of 8 percent and organic growth of 4 percent in the first quarter. This compares to the $2.31 billion it reported in the prior year quarter.
The net income attributable to Willis Towers Watson for the first quarter of 2020 was $305 million, an increase of 6 percent from $287 million for the prior-year first quarter. The net income included pre-tax $9 million of transaction and integration expenses mostly related to the pending business combination with Aon.
John Haley, Willis Towers Watson’s chief executive officer, highlighted that the company remains "well-positioned" and resilient during the pandemic.
“Willis Towers Watson executed well in the first quarter while navigating the unprecedented challenges brought on by the COVID-19 pandemic,” said Haley. “I would like to personally acknowledge and thank our colleagues for remaining steadfast in supporting our clients and each other through a very challenging environment.
"We are dealing with extraordinary times, but I am pleased to say our resilience, experience and business continuity plans have enabled us to operate at a high level globally, and we believe we remain well-positioned to manage through this difficult period, while continuing to serve our clients, engage our colleagues and deliver value for our shareholders."
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Elliot Field at efield@newtonmedia.co.uk or Adrian Tapping at atapping@newtonmedia.co.uk
Editor's picks
Editor's picks
More articles
Copyright © intelligentinsurer.com 2024 | Headless Content Management with Blaze